EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Impact of Semaglutide on fat mass, lean mass and muscle function in patients with obesity: The SEMALEAN study

Mathieu Alissou, Thomas Demangeat, Vanessa Folope, Hélène Van Elslande, Hélène Lelandais, Julia Blanchemaison, Pierre-Emmanuel Cailleaux, Suzan Guney, Alexandra Aupetit, Agnès Aubourg, Clément Rapp, André Petit und 7 weitere

Diabetes, Obesity and Metabolism · 2026-01 · 28 (1) · 112-121

DOI: 10.1111/dom.70141 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Diabetes, Obesity and Metabolism, online erschienen am 09.10.2025. Verfasst von Mathieu Alissou und 18 weiteren Autor:innen. Beteiligte Einrichtung: Department of Nutrition and CIC-CRB 1404, CSO Rouen Normandie, CHU Rouen, Rouen, France. Hauptthemen laut MEDLINE: Obesity, Glucagon-Like Peptides, Body Composition, Muscle, Skeletal. Die Arbeit wurde bisher 88-mal zitiert (Crossref) und nennt 31 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Aims

Semaglutide, a GLP‐1 receptor agonist, has shown efficacy in promoting weight loss. However, limited data exist on its impact on lean mass, muscle function, and metabolic adaptations. The SEMALEAN study aims to evaluate these parameters in patients with obesity treated with Semaglutide (2.4 mg). Materials and Methods This prospective study enrolled 115 patients with obesity between February 2022 and November 2024. Body weight, body composition (measured by DXA), muscle function (handgrip strength), and resting energy expenditure (REE) were assessed at baseline (M0), 7 months (M7), and 12 months (M12). Subgroup analyses examined the impact of sex, type 2 diabetes, previous GLP‐1 use, and history of bariatric surgery.

Results

A total of 106 patients (68.9% female; mean BMI 46.3 kg/m 2 ) completed the study. Weight loss was significant, with mean reductions of 10% at M7 and 13% at M12; 59% of patients achieved ≥10% weight loss. Total fat mass decreased by 14% at M7 and 18% at M12, while lean mass initially declined (−3 kg at M7) but stabilised thereafter. Handgrip strength improved significantly (+4.5 kg at M12), and the prevalence of sarcopenic obesity decreased from 49% at baseline to 33% at M12. REE normalised to lean mass increased significantly from M7 to M12. Subgroup analyses revealed greater weight and fat mass loss in women, while patients with type 2 diabetes or prior GLP‐1 analogue use showed attenuated responses. Patients with a history of bariatric surgery exhibited the most pronounced reductions in body composition parameters.

Conclusions

The SEMALEAN study highlights the significant impact of Semaglutide 2.4 mg on weight loss, fat mass reduction, and muscle function improvement, with preserved lean mass and metabolic efficiency. These findings underscore the importance of a comprehensive approach to obesity management, addressing not only weight loss but also functional and metabolic adaptation.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

ObesityGlucagon-Like PeptidesBody CompositionMuscle, SkeletalAdipose TissueHumansFemaleMaleMiddle AgedProspective StudiesWeight LossAdultHand StrengthDiabetes Mellitus, Type 2Energy MetabolismGlucagon-Like Peptide 1Semaglutide

Stichwörter der Autor:innen

Semaglutideantiobesity drugbody compositionobesity care

Substanzen

Glucagon-Like PeptidesGlucagon-Like Peptide 1Semaglutide

Autor:innen und Institutionen

  • Department of Nutrition and CIC-CRB 1404, CSO Rouen Normandie, CHU Rouen, Rouen, France.
  • Univ Rouen Normandie, INSERM, Normandie Univ, ADEN UMR 1073 "Nutrition, Inflammation and Microbiota-Gut-Brain Axis", Rouen, France.

ORCID-Profile: Moïse Coëffier

Zitieren

APA

Alissou, M., Demangeat, T., Folope, V., Van Elslande, H., Lelandais, H., Blanchemaison, J., Cailleaux, P. E., Guney, S., Aupetit, A., Aubourg, A., Rapp, C., Petit, A., Godin, M., Vignal, L., Grigioni, S., Déchelotte, P., Colange, G., Coëffier, M., & Achamrah, N. (2026). Impact of Semaglutide on fat mass, lean mass and muscle function in patients with obesity: The SEMALEAN study. Diabetes, Obesity and Metabolism, 28(1), 112-121. https://doi.org/10.1111/dom.70141

Vancouver

Alissou M, Demangeat T, Folope V, Van Elslande H, Lelandais H, Blanchemaison J, et al. Impact of Semaglutide on fat mass, lean mass and muscle function in patients with obesity: The SEMALEAN study. Diabetes, Obesity and Metabolism. 2026;28(1):112-121. doi:10.1111/dom.70141

BibTeX
@article{Alissou2026,
  author = {Alissou, Mathieu and Demangeat, Thomas and Folope, Vanessa and Van Elslande, Hélène and Lelandais, Hélène and Blanchemaison, Julia and Cailleaux, Pierre-Emmanuel and Guney, Suzan and Aupetit, Alexandra and Aubourg, Agnès and Rapp, Clément and Petit, André and Godin, Morgane and Vignal, Luc and Grigioni, Sébastien and Déchelotte, Pierre and Colange, Guillaume and Coëffier, Moïse and Achamrah, Najate},
  title = {Impact of Semaglutide on fat mass, lean mass and muscle function in patients with obesity: The SEMALEAN study},
  journal = {Diabetes, Obesity and Metabolism},
  year = {2026},
  volume = {28},
  number = {1},
  pages = {112--121},
  doi = {10.1111/dom.70141}
}
Kostenlos starten →